Searchable abstracts of presentations at key conferences in endocrinology

ea0080p1 | Abstracts | UKINETS2021

Setting up of a national liver transplant programme for neuroendocrine tumour liver metastases in UK and Ireland: opportunities for clinical study and research

Shah Tahir , Moore Joanna , Venkataraman Hema , Caplin Martyn , Smith Stacey , O'Toole Dermot , Hoti Emir , Dasari Bobby , Ford Samuel , Mazzaferro Vincenzo , Gibbs Paul , Manas Derek , Isaac John , Thorburn Douglas

Background: Transplantation for cancer indications is evolving rapidly in UK and Ireland. Liver transplantation [LT] for unresectable neuroendocrine tumour liver metastases [NET LM] is one of three new cancer indications. It has the potential to significantly improve survival outcomes however, transplant benefit has likely been achieved only by highly experienced Centre(s). Since eligible patients for transplantation also have excellent prognosis with standard management, care...

ea0051p027 | Miscellaneous/other | BSPED2017

Is there an association between endocrine conditions, including growth hormone deficiency, and Chiari-1 Malformation? A retrospective single centre study

Elhag Sabba , Shah Jamie , Krone Ruth , Kershaw Melanie , Shaw Nick , Barrett Timothy , Kirk Jeremy , Saraff Vrinda , Hogler Wolfgang , Solanki Guirish , Dias Renuka

Introduction: Chiari-1 malformation (C-1M) is defined as the crowding of the craniocervical junction as a result of congenital cerebellar tonsil descent past the foramen magnum. Reported association between endocrine disorders and C-1M is mostly anecdotal.Aims: To evaluate the prevalence of endocrine disorders in C-1M against the prevalence of C-1M in those with isolated Growth Hormone Deficiency (GHD) with the aim of determining if there is a significan...

ea0050p401 | Thyroid | SFEBES2017

Does presence of ‘Coexisting Thyroiditis’ affect Radioiodine Uptake in Thyroid Cancer Ablation Doses?

Shah Shanty George , Waterhouse Mona , Akker Scott , Drake William , Plowman Nick , Berney Daniel M , Richards Polly , Adams Ashok , Nowosinska Ewa , Brennan Carmel , Druce Maralyn

Background: Patients being treated for differentiated thyroid cancer (DTC) receive a dose of Radioiodine for remnant ablation. Occasional patients appear to have little or no iodine uptake at all in the thyroid bed or else where even shortly after thyroidectomy.Objective: To evaluate the influence of ‘Coexisting Thyroiditis’ on radioiodine uptake in thyroid cancer ablation doses.Methods and Design: Retrospec...

ea0050p401 | Thyroid | SFEBES2017

Does presence of ‘Coexisting Thyroiditis’ affect Radioiodine Uptake in Thyroid Cancer Ablation Doses?

Shah Shanty George , Waterhouse Mona , Akker Scott , Drake William , Plowman Nick , Berney Daniel M , Richards Polly , Adams Ashok , Nowosinska Ewa , Brennan Carmel , Druce Maralyn

Background: Patients being treated for differentiated thyroid cancer (DTC) receive a dose of Radioiodine for remnant ablation. Occasional patients appear to have little or no iodine uptake at all in the thyroid bed or else where even shortly after thyroidectomy.Objective: To evaluate the influence of ‘Coexisting Thyroiditis’ on radioiodine uptake in thyroid cancer ablation doses.Methods and Design: Retrospec...

ea0087p2 | Poster Presentations | UKINETS2022

PREF-NET: a patient preference and experience study of lanreotide autogel administered in the home versus hospital setting among patients with gastroenteropancreatic neuroendocrine tumours in the UK

Khan Mohid , Davies Louise , Back Melissa , Shah Tahir , Pritchard Mark , Cook Kathryn , Hull Diana , McKane Gail , Day Melissa , Grandoulier Anne-Sophie , Higgs Kate

Introduction: LAN, a somatostatin analogue, is a common first-line treatment for NETs. LAN comes as a pre-filled, ready-to-use syringe, administered every 4 weeks. In the UK, patients may receive LAN at home. The aim of PREF-NET was to generate real-world evidence describing patient’s experience of LAN administered in homecare and hospital settings, and the associated impact of treatment setting on other areas of patients’ lives.Methods: PREF-N...

ea0089t9 | Trials In Progress | NANETS2022

PReCedeNT Trial: Phase III Randomised Controlled Trial of PRRT with Lutetium – 177 DOTATATE Plus Chemotherapy vs PRRT Alone in FDG-avid, Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors

D Puranik Ameya , Rangarajan Venkatesh , Ramaswamy Anant , Ostwal Vikas , V Shrikhande Shailesh , Bhandare Manish , Chaudhari Vikram , M Bal Munita , Agrawal Archi , C Purandare Nilendu , Shah Sneha

Background: Well-differentiated GEP NETs show positive uptake on Ga-68-DOTATOC PET/CT, a somatostatin-receptor (SSTR)-specific imaging tracer. 18F-FDG PET/CT is preferred for aggressive, high-grade NETs as GLUT (glucose-transporter) receptor expression entails poorer prognosis. Grade 2 NET may demonstrate heterogenous uptake of both tracers; suggestive of tumor heterogeneity. PRRT is widely available at reasonable cost since Lu-177-DOTATATE is manufactured indegenously, and is...

ea0065cc8 | FEATURED CLINICAL CASE POSTERS | SFEBES2019

Well-differentiated grade 3 neuroendocrine tumors (G3NET) – single centre experience from the UK

Venkataraman Hema , Lithgow Kirstie , Smith Stacey , Kemp-Blake Joanne , Vickrage Suzanne , Hughes Simon , Shetty Shishir , Elshafie Mona , Gadvi Rakesh , Kharkhanis Salil , Ayuk John , Geh Ian , Shah Tahir

Introduction: The WHO classification distinguishes G3NET as a separate entity. Literature on G3NETs is limited to case-reports and small case-series. We aimed to characterise G3NETs from a large tertiary centre.Methods: Retrospective analysis from NET database: 2012–2019. All referrals are discussed at a specialist NET-MDT before entry into clinical pathway. Core NET-MDT consists of a radiologist, nuclear-medicine radiologist, histopathologist, spec...

ea0065p239 | Metabolism and Obesity | SFEBES2019

Weight loss and change in obesity related comorbidities in patients undergoing laparoscopic adjustable gastric banding at UHCW between 2009 and 2012

Leca Bianca , Dimitriadis Georgios K , Khan Uzma , Abraham Jenny , Halder Louise , Shuttlewood Emma , Shah Neha , Barber Thomas M , Menon Vinod , Randeva Harpal S

Background: The Royal College of Physicians (RCP) called earlier this year for obesity to urgently be recognized as a disease, and warned that until this happens its prevalence is unlikely to be reduced. Obesity is associated with multiple comorbidities, including type 2 diabetes mellitus (T2DM), hypertension (HT), and dyslipidemia. Bariatric surgery (BS) produces dramatic weight loss, with improvement of obesity associated comorbidities and decrease of overall mortality.<...

ea0046p31 | (1) | UKINETS2016

A single centre analysis of the management of appendiceal neuroendocrine neoplasms (NENs) including goblet cell carcinoids (GCC)

Sagar Vandana , Coldham Christopher , Shah Tahir , Setty Shishir , Ayuk John , Elshafie Mona , Taniere Phillipe , Gourevitch David , Desai Anant , Ford Samuel , Karkhanis Salil , Geh Ian

Introduction: Appendiceal NENs are usually diagnosed incidentally on histology following an appendicectomy. They include carcinoid tumours (appendiceal neuroendocrine tumours, NETs) and GCC. GCC neoplasms are able to transform to an adenocarcinoma phenotype. There are several important criteria to review when deciding on the treatment and follow up for appendiceal NENs, in particular when to offer further surgery to patients.Aim: To assess whether the ma...

ea0044oc1.4 | Early Career Oral Communications | SFEBES2016

The urinary steroid metabolome as a non-invasive tool to stage non-alcoholic fatty liver disease

Moolla Ahmad , Amin Amin , Hughes Bev , Arlt Wiebke , Hassan-Smith Zaki , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Biehl Michael , Tomlinson Jeremy

Introduction: Dysregulation of glucocorticoid (GC) metabolism is implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The only available treatment for NAFLD is weight loss and the gold standard diagnostic test is liver biopsy, which is invasive and resource intensive. NAFLD ranges from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and cirrhosis. It may be regarded as the hepatic manifestation of the metabolic syndrome and is strongl...